Who are YPEG-rhG-CSF's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Neulasta, Neupogen, rhG-CSF+rhGM-CSF group, LENOGRASTIM (GRANOGYTE 34), Late receiving G-CSF group, Pegylated rhG-CSF regimen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ypeg-rhg-csf.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

YPEG-rhG-CSF — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

YPEG-rhG-CSF (YPEG-rhG-CSF) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: G-CSF agonist. Area: Oncology.

phase 3 G-CSF agonist G-CSF receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

YPEG-rhG-CSF (YPEG-rhG-CSF) — Xiamen Amoytop Biotech Co., Ltd.. PEG-rhG-CSF is a recombinant human granulocyte colony-stimulating factor (G-CSF) conjugated with polyethylene glycol (PEG), which helps stimulate the production of white blood cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
YPEG-rhG-CSF TARGET	YPEG-rhG-CSF	Xiamen Amoytop Biotech Co., Ltd.	phase 3	G-CSF agonist	G-CSF receptor
Neulasta	Pegfilgrastim-Apgf	Amgen	marketed	Colony-stimulating factor	G-CSF receptor on hematopoietic cells	2002-01-01
Neupogen	Filgrastim-Aafi	Amgen	marketed	Colony-stimulating factor (CSF); leukocyte growth factor	G-CSF receptor (granulocyte colony-stimulating factor receptor)	1991-01-01
rhG-CSF+rhGM-CSF group	rhG-CSF+rhGM-CSF group	Xiamen Amoytop Biotech Co., Ltd.	marketed	Hematopoietic growth factor combination	G-CSF receptor; GM-CSF receptor
LENOGRASTIM (GRANOGYTE 34)	LENOGRASTIM (GRANOGYTE 34)	Sanofi	marketed	Granulocyte colony-stimulating factor (G-CSF)	G-CSF receptor (GCSFR)
Late receiving G-CSF group	Late receiving G-CSF group	Department of Medical Services Ministry of Public Health of Thailand	marketed	Cytokine; Hematopoietic growth factor	G-CSF receptor (GCSFR)
Pegylated rhG-CSF regimen	Pegylated rhG-CSF regimen	Shandong Provincial Hospital	marketed	G-CSF receptor agonist	G-CSF receptor (CSF3R)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (G-CSF agonist class)

Chinese Academy of Medical Sciences · 2 drugs in this class
Asan Medical Center · 1 drug in this class
Centre Leon Berard · 1 drug in this class
Recardio, Inc. · 1 drug in this class
Xiamen Amoytop Biotech Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). YPEG-rhG-CSF — Competitive Intelligence Brief. https://druglandscape.com/ci/ypeg-rhg-csf. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing